Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- 1 March 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 109, 12-20
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost AnalysisClinical Pharmacology & Therapeutics, 2017
- Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response AnalysisClinical Pharmacology & Therapeutics, 2017
- Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid TumorsCPT: Pharmacometrics & Systems Pharmacology, 2016
- Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid TumorsThe Journal of Clinical Pharmacology, 2016
- Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesThe Journal of Clinical Pharmacology, 2015
- Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2014
- Pharmacokinetics and Pharmacodynamics of Monoclonal AntibodiesBioDrugs, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRnAnnual Review of Immunology, 2000
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying ImmunoreceptorImmunity, 1999